Melatonin as a Longevity Molecule? Safety Data, Metabolic Risks, and Antioxidant Promise

Beyond Sleep: Melatonin’s Systems Biology—Mitochondria, Immune, and Hormonal Crosstalk

We’ve been taught to think of melatonin as the body’s sleep hormone—a messenger of darkness, signaling when it’s time to rest.

But that framing barely scratches the surface.

Melatonin doesn’t just tell the brain it’s night.

It moves through nearly every major system: reducing mitochondrial oxidative stress, modulating immune function, suppressing inflammatory signaling, and interacting with hormonal pathways few associate with sleep. In certain contexts, its actions resemble those of a regulatory hormone more than a simple chronobiotic.

This complexity is both its promise and its problem.

In many cases, melatonin can support redox balance, mitochondrial resilience, and age-related defense. But in non-physiological or pharmacological doses—or when used chronically—it can disrupt glucose metabolism, suppress synaptic plasticity, and alter reproductive signaling.

➔ Even its antioxidant behavior, often considered universally protective, can flip to pro-oxidant in vitro under specific metabolic conditions.

➔ Mistimed or high-dose use has been shown to impair insulin sensitivity and blunt hippocampal signaling essential for memory.

➔ Some data suggest possible interference with reproductive hormones and immune homeostasis—especially in vulnerable populations.

What follows is a layered examination of melatonin’s dual nature: why it has drawn interest as a longevity molecule, where its benefits seem compelling, and where its risks suggest caution.

➤ Section 2 — Melatonin as a Longevity Molecule: Mitochondria, Antioxidant Defense, and Redox Biology

Melatonin exhibits a robust capacity to reduce oxidative stress across a wide range of cellular environments. It acts through both direct and indirect mechanisms:

➔ Directly neutralizing reactive oxygen species (ROS) and reactive nitrogen species (RNS), including some of the most damaging radicals in biological systems.

➔ Indirectly enhancing the cell’s antioxidant defense by increasing the activity of endogenous antioxidant enzymes and reducing the activity of enzymes that generate free radicals.

Additionally, melatonin is capable of chelating transition metals that participate in the Fenton and Haber-Weiss reactions—critical drivers of hydroxyl radical formation. This allows melatonin to suppress oxidative cascades before they can propagate significant cellular damage.

Its intracellular distribution is also relevant. Melatonin accumulates in mitochondria—one of the primary sources of ROS production in the cell. This localization contributes to its ability to prevent mitochondrial dysfunction and reduce apoptosis under oxidative stress conditions. These characteristics support the classification of melatonin as a mitochondria-targeted antioxidant.

Section 2.1 Melatonin–Mitochondria Antioxidant Actions: ROS/RNS Scavenging and Redox Enzyme Modulation

Beyond its role in circadian regulation, melatonin functions as a broad-spectrum antioxidant. It directly scavenges harmful radicals such as hydroxyl, peroxyl, and nitric oxide species. It also amplifies the body’s natural antioxidant systems by upregulating enzymes like glutathione peroxidase, superoxide dismutase, and catalase, while simultaneously suppressing pro-oxidant enzymes like nitric oxide synthase and lipoxygenase .

These functions have been documented in both in vitro and in vivo models. For example, melatonin has demonstrated protective effects against oxidative injury in the brain during ischemic stroke, in the myocardium during infarction, and in models of drug-induced toxicity. Across these systems, its antioxidant actions are consistently linked to reductions in inflammation and preservation of mitochondrial membrane integrity .

Melatonin’s antioxidant capacity is not limited to membrane compartments. It crosses cell membranes and enters subcellular structures, including mitochondria, where it directly counters oxidative stress at its point of origin. This has led to comparisons with vitamin E—another lipid-soluble antioxidant. In head-to-head assessments, melatonin has been shown to provide more comprehensive protection across aqueous and lipid environments.

Because of these features, melatonin has been explored as an adjunct in a range of oxidative stress–related conditions, including neurodegenerative disease, cancer therapy, and inflammatory disorders. Its ability to act at the mitochondrial level while regulating broader redox dynamics is a central reason for this interest.

➔ Next, we examine how these antioxidant properties influence aging in two systems particularly vulnerable to oxidative stress: the brain and the cardiovascular system.

Section 2.2 Cardiovascular & Neurodegenerative Aging: Melatonin, Mitochondrial Resilience, and Sirtuin Pathways

Mechanistically, melatonin functions as a multi-targeted signaling molecule that modulates several hallmarks of aging—most notably mitochondrial dysfunction, chronic inflammation, and loss of cellular resilience. These roles become particularly relevant in the context of cardiovascular and neurodegenerative aging.

➤ Cardiovascular Aging: Endothelial Function, Mitochondrial Dynamics, Nrf2, and Telomere Support

Aging cardiomyocytes and vascular cells display mitochondrial decline: impaired oxidative phosphorylation, elevated ROS production, altered calcium handling, and increased apoptotic signaling. Melatonin counters these effects through several converging pathways:

➔ It preserves mitochondrial membrane integrity by stabilizing cardiolipin and preventing the opening of the mitochondrial permeability transition pore.

➔ It activates sirtuins, particularly SIRT1 and SIRT3, which restore redox balance, support mitophagy, and inhibit pro-apoptotic signaling (↑ Bcl-2, ↓ Bax).

➔ In myocardial aging and ischemia-reperfusion models, melatonin reduced infarct size, restored NAD⁺/NADH balance, and improved mitochondrial dynamics.

➔ It suppressed inflammatory cytokines like IL-1β and IL-6, while upregulating Nrf2 and improving endothelial nitric oxide (NO) signaling.

➔ In vascular smooth muscle cells, melatonin prevented senescence and calcification via exosomal microRNAs (miR-204/211).

➔ It enhanced telomerase activity in vascular tissue and reduced oxidative DNA damage—delaying senescence at the genomic level.

The cumulative effect is restoration of mitochondrial efficiency, suppression of inflammaging, protection of endothelial function, and reduced risk of age-related arrhythmia, fibrosis, and vascular stiffness.

➤ Neurodegenerative Aging: Melatonin, Synaptic Resilience, Autophagy, and Neuroinflammation

Neurons, due to their high metabolic demands, are particularly vulnerable to redox imbalance, mitochondrial decline, and excitotoxicity. With aging, these stressors are compounded by protein misfolding, impaired autophagy, and loss of neurotrophic signaling.

Melatonin acts at several points in these pathological cascades:

➔ It boosts sirtuin activity (SIRT1, FOXO1/3a), enhancing autophagy, reducing apoptosis, and preserving mitochondrial function.

➔ It suppresses NF-κB, NLRP3 inflammasome, and glial activation—curbing neuroinflammation.

➔ It protects blood-brain barrier integrity via NADPH oxidase inhibition, AMPK activation, and reduced MMP-9 expression.

➔ In Alzheimer’s disease models, melatonin reduces amyloid and tau pathology by restoring mitophagy and regulating phosphorylation/dephosphorylation cycles.

➔ It supports synaptic plasticity via upregulation of BDNF, NMDA receptor subunits, and CAMKII, while reducing astrocytic and microglial activation.

➔ In Parkinson’s models, it attenuates α-synuclein aggregation, preserves dopaminergic neurons, and modulates microglia-mediated neurotoxicity.

➔ Post-stroke, it limits damage by activating SIRT1, reducing pro-inflammatory cytokines, and inhibiting apoptotic pathways.

Each of these actions converges on a central mechanism: the defense and restoration of mitochondrial and genomic integrity in aging neural circuits.

Summary chart of melatonin’s anti-aging effects, Description: Mechanism-specific table highlighting melatonin’s action across mitochondrial function, inflammation, sirtuins, autophagy, and neurovascular protection:

Melatonin’s regulatory effects span systems but converge on a consistent anti-aging architecture: mitochondrial protection, redox balance, and suppression of chronic inflammation.

Melatonin’s protective footprint spans neural, vascular, and metabolic systems—but the outcomes in humans depend on several variables: dose, timing, baseline melatonin levels, and underlying physiological state

Which raises an important question:

➔ If melatonin exhibits such wide-reaching antioxidant benefits, should healthy individuals supplement with it routinely—or even in high doses, regardless of whether they use it for sleep?

➔ If someone were using it for sleep, should they stop if it doesn’t work, or continue due to its potential non-sleep related benefits?

That’s where the data gets more complicated.

➔ Up next: What the evidence reveals about metabolic, neurological, and hormonal risks associated with melatonin use.

➤ Section 3 — Melatonin Risks at High Dose: Metabolic, Neural, Reproductive, and Immune Trade-offs

While melatonin’s antioxidant and anti-aging properties have attracted significant attention, emerging research shows that its benefits—and risks—depend heavily on variables like dose, timing of dose, baseline melatonin levels, and the user’s metabolic or immune status

And contrary to what cursory internet look-up suggests, melatonin’s effects are not limited to daytime sleepiness or headache.

Rather, exogenous melatonin—especially with high or repeated doses—may

• impair glucose regulation,
• reduce synaptic plasticity,
• disrupt reproductive hormones,
• alter immune signaling,
• promote oxidative stress

To understand where these concerns arise, we need to examine the systems most sensitive to exogenous melatonin—starting with glucose metabolism.

Section 3.1 Melatonin and Glucose Metabolism: Impaired Glucose Tolerance and Insulin Sensitivity

Exogenous melatonin has been shown to interfere with glucose regulation in both healthy individuals and people with metabolic disease.

➤ Healthy adults — melatonin and glucose metabolism: OGTT impairment, timing, and insulin dynamics

In a controlled study of 21 healthy adults (mean age 24, BMI ~23), a 5 mg dose of melatonin taken before a glucose tolerance test significantly impaired glycemic control compared to placebo. When administered in the morning, melatonin raised glucose AUC  (area under the curve) by approximately 186% and peak glucose by 21%. Even when taken in the evening, it still caused a 54% increase in AUC.

Mechanistically, the impairment was time-dependent: morning melatonin reduced insulin secretion, while evening melatonin reduced insulin sensitivity.

These results highlight that proximity to food intake plays a critical role in how melatonin influences glucose metabolism. Even in young and healthy individuals, melatonin may acutely worsen glucose tolerance depending on dosage and timing.

➤ Type 2 diabetes — high-dose melatonin risks: reduced insulin sensitivity and secretion

In metabolically vulnerable populations, melatonin’s effects appear even more pronounced.

A double‐blinded, randomized, placebo‐controlled, crossover trial involving 17 men with type 2 diabetes found that taking 10 mg of melatonin nightly, 1-hour before bedtime for 3-months reduced insulin sensitivity by ~12%.

The reduction in insulin sensitivity was assessed by an intravenous glucose tolerance test (0.3 g/kg) and measured by hyperinsulinemic-euglycemic clamp—a gold-standard method where insulin is infused to maintain steady glucose levels, allowing precise assessment of how much glucose the body absorbs in response.

This was also accompanied by reductions in glucose-stimulated insulin secretion and suggests that melatonin negatively affected both insulin release and peripheral sensitivity.

The authors concluded that high-dose melatonin should be used cautiously in people with existing glucose dysregulation, given the potential for exacerbating insulin resistance.

However, beyond metabolic effects, melatonin also interacts with neural pathways in the brain—especially those involved in plasticity and memory.

Section 3.2 Neural Effects: MT1/MT2 Signaling, Hippocampal Plasticity, Memory, and High-Dose Risk

That concern becomes more relevant when we consider melatonin’s widespread presence in the brain—particularly outside its role in sleep regulation.

Melatonin’s distribution in the central nervous system (CNS) extends well beyond the suprachiasmatic nucleus—the brain’s master clock that synchronizes circadian rhythms in response to light. It acts through two primary receptor types, MT₁ and MT₂—proteins on the surface of neurons that respond to melatonin and trigger downstream signaling.

MT₂ receptors, in particular, are found throughout the brain, including the hippocampus, amygdala, and olfactory structures—suggesting melatonin may influence neural processes outside circadian regulation.

One potentially concerning effect is melatonin’s suppression of long-term potentiation (LTP), a synaptic mechanism critical for learning and memory.

In mouse hippocampal slice experiments, exposure to 100 nM melatonin reduced LTP magnitude by approximately 50%. The suppression was dose-dependent, and involved inhibition of the cAMP/PKA signaling pathway via MT₂ receptors.

Given that LTP is a key process in memory consolidation, these findings raise questions about melatonin’s impact on cognitive function—especially under chronic, high-dose conditions.

The idea that melatonin could dampen neuroplasticity seems to remain under-explored at this time but mechanistically plausible.

Further studies are needed to evaluate whether exogenous melatonin—especially taken during waking hours or in pharmacological doses—may unintentionally impair memory formation or learning capacity.

Although data on learning circuits remain limited, the presence of melatonin receptors in multiple brain regions invites a broader question: if melatonin can suppress signaling in the hippocampus, what are its effects in other tissues that also express its receptors?

One system where this question is also relevant is the reproductive axis.

Section 3.3 Reproductive Hormones & Fertility: Melatonin Receptor Signaling Across the HPG Axis

Melatonin’s influence on reproductive signaling is more directly supported by existing research. In humans, MT₁ and MT₂ receptors are present throughout the hypothalamic-pituitary-gonadal (HPG) axis: in the hypothalamus (regulating gonadotropin-releasing hormone, or GnRH), the anterior pituitary (modulating the release of luteinizing hormone [LH] and follicle-stimulating hormone [FSH], which govern ovulation and testosterone production), and the gonads—including both testes and ovaries—where they may influence steroid hormone production and local reproductive signaling.

Human studies have explored whether this receptor distribution translates into functional changes in reproductive hormones and fertility outcomes.

➤ Human studies — melatonin and reproductive hormones: semen quality, aromatase, and HPG axis signaling

In a double-blind crossover study, 8 healthy men were given either 3 mg of melatonin or placebo daily for 6-months. Semen quality, serum and seminal hormone levels, and gonadotropins were assessed throughout.

In 6 of the participants, no significant changes were noted. However, 2 men showed a marked decline in sperm concentration (to 3 × 10⁶/mL and 12 × 10⁶/mL, respectively) and motility (to 32% and 30%).

After discontinuing melatonin for 6 months, sperm parameters returned to baseline in one of the affected men, but remained abnormal in the other. The authors proposed that melatonin may inhibit testicular aromatase activity, thereby reducing estradiol synthesis without altering gonadotropin levels.

In rare clinical cases, elevated melatonin levels have been linked to delayed puberty or hypogonadism—a condition characterized by reduced sex hormone production and impaired sexual development. While not conclusive, these observations raise the possibility that exogenous melatonin at standard over-the-counter doses could impact male reproductive health—even in the absence of changes to upstream pituitary hormones.

➤ Animal models — photoperiod signaling: melatonin, LH/FSH suppression, and fertility timing

In seasonally breeding mammals, melatonin plays a role in regulating fertility according to photoperiod. In long-day breeders such as hamsters or sheep, elevated melatonin during extended dark periods suppresses the reproductive axis. This involves inhibition of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary. Conversely, in short-day breeders, melatonin acts as a cue to initiate reproduction during winter months.

When administered out of phase with normal circadian or seasonal rhythms, melatonin can suppress gonadotropin levels and induce hypogonadotropic states in animal models. This suggests a plausible pathway by which chronic or high-dose melatonin could blunt reproductive signaling in humans as well.

While human data remain limited, these animal models highlight how sensitive reproductive signaling can be to melatonin’s timing and dose. So far, we’ve examined its impact on glucose metabolism, neural signaling, and reproductive hormones—all systems where dose and timing matter.

But that’s not the full picture.

Melatonin also interacts with the immune system—where its signaling appears both therapeutically promising and, under some conditions, potentially disruptive.

Section 3.4 Immune Modulation: When Melatonin Signals Pro-Inflammatory vs Anti-Inflammatory Responses

Melatonin is widely recognized for its anti-inflammatory properties.

However, there are evidence that suggest its effects on the immune system are bidirectional—dependent on context, timing, and immune status.

In isolated immune cells, including human leukocytes and Th1/Th17 lymphocytes, melatonin has been shown to increase production of several pro-inflammatory cytokines. These include IL‑1β, IL‑2, IL‑6, TNF‑α, IFN‑γ, and IL‑17. This stimulatory effect may reflect a physiological role in priming the immune system—particularly in the early morning hours, and is not necessarily a pathological process.

In autoimmune diseases such as rheumatoid arthritis (RA), however, this same mechanism may become maladaptive. RA patients have been found to exhibit elevated melatonin levels during the night and early morning—timing that coincides with symptom flares like joint stiffness and increased inflammatory activity. In this setting, melatonin may amplify Th1 and Th17 responses, intensifying inflammation rather than resolving it, and as a result, exacerbate joint damage and discomfort.

This dual behavior—anti-inflammatory under some conditions, pro-inflammatory under others—emerges across multiple models:

These findings suggest that melatonin’s immune effects are context-sensitive. In individuals with autoimmune predisposition or heightened immune tone, melatonin may unintentionally exacerbate inflammatory signaling.

A similar pattern of dual effects has been observed in another core system: redox balance. Although melatonin is typically described as an antioxidant, under certain cellular or metabolic conditions, it may instead promote oxidative activity.

➔ In the next section, we examine how melatonin’s redox behavior can shift from protective to potentially pro-oxidant.

Section 3.5 High-Dose Melatonin as Pro-Oxidant: Dose-Dependent Redox Shifts and Mitochondrial ROS

Melatonin is most often described as an antioxidant, with well-documented effects on mitochondrial protection and oxidative stress reduction.

However, under certain conditions—especially at high concentrations—it has demonstrated the opposite effect: promoting the generation of reactive oxygen species (ROS).

In cell culture studies using pharmacological doses of melatonin (in the micromolar to millimolar range), melatonin has been shown to increase intracellular ROS levels. These pro-oxidant effects were observed in both tumor and non-tumor cell lines.

Mechanistically, melatonin may promote ROS formation by:

• Activating calmodulin, which stimulates phospholipase A2 (PLA2) and downstream 5-lipoxygenase (5‑LOX), leading to pro-oxidant lipid mediators.
• Interacting directly with mitochondrial complex III or the mitochondrial permeability transition pore (MPTP), potentially enhancing electron leak and ROS production.

These findings raise the possibility that at high enough concentrations—melatonin could exert cytotoxic or pro-oxidant effects. However, such effects have mainly been reported in vitro, and researchers caution that “whether the reported in vitro pro-oxidant actions come into play in live organisms remains to be established.”

In summary, while melatonin is typically antioxidant under physiological conditions, the possibility of dose-dependent pro-oxidant behavior in cells invites careful consideration. Although pro-oxidant effects have not been demonstrated in humans, their biological plausibility warrants attention, especially in the context of high-dose supplementation.

Absence of evidence is not evidence of absence.

This brings us to a more grounded question: given the range of mechanisms covered so far—metabolic, neural, endocrine, immune, and oxidative—what do we actually know about the safety of melatonin supplementation in humans, especially at doses that exceed endogenous levels?

➔ With these concerns in view, the next section examines clinical safety data—what’s been observed, what’s still unclear, and where the research falls short.

➤ Section 4 — Melatonin Safety Data: What High-Dose Trials and Meta-Analyses Show

Although melatonin is often perceived as harmless, formal safety data—especially for high doses, used over a long period of time—remain surprisingly sparse. Adverse event (AE) reporting is inconsistent across trials, and only a minority of studies meet rigorous criteria for bias control.

Melatonin users are the unwitting subjects in a large-scale uncontrolled experiment. NIH, 1996

In a 2022 systematic review and meta-analysis by Menczel Schrire et al., 79 studies encompassing 3,861 participants were assessed for safety outcomes. These included individuals with a broad range of health conditions, and melatonin dosages varied substantially. Notably:

• 29 of the 79 studies (37%) provided no adverse event (AE) data at all.
• Only 4 out of the 79 studies met low-risk-of-bias criteria sufficient for quantitative synthesis.

Within this rigorously selected subset, melatonin did not increase serious adverse events (SAEs) or withdrawals due to AEs:

• SAEs: Rate Ratio = 0.88 [0.52, 1.50], p = .64
• Withdrawals due to AEs: RR = 0.93 [0.24, 3.56], p = .92

However, melatonin did increase the rate of general AEs, such as drowsiness, dizziness, and headache:

• Overall AE risk: RR = 1.40 [1.15, 1.69], p < .001

The researchers note that while melatonin appears safe in the short term, especially for common side effects, its long-term safety remains inadequately evaluated—particularly at high doses. They cite the NIH’s 1996 warning that melatonin users may be participating in a “large-scale uncontrolled experiment,” and conclude that additional, long-duration trials with comprehensive AE tracking are still needed.

Twenty-five years later, the current study still finds that additional studies in adults, using higher doses for longer durations are needed, with comprehensive reporting on AEs to confirm the current widespread belief that melatonin is indeed safe. Menczel Schrire 2022

Subsequent reviews have expanded on this question.

In a 2023 review by Givler et al., low-to-moderate daily doses (typically ≤5–6 mg) were described as “generally safe,” with long-term benefits observed in some patient groups, including individuals with autism. However, here, the researchers also emphasized that data on chronic high-dose use are still limited, especially in the context of aging and neurodegenerative prevention.

➤ Section 5. Melatonin for Longevity vs Sleep: Context, Dose, Timing, and When Not to Supplement

Melatonin has been studied as both a circadian hormone and a longevity candidate. The mechanistic promise is clear, but so are the gaps: long-term, high-dose use hasn’t been well tested, and risks appear when dose, timing, or baseline physiology are mismatched.

That means whether you’re thinking about melatonin for sleep or for longevity, the decision has to be intentional and measured. The real question isn’t just “does it work?” but “does it work for me — in this context, at this dose, at this timing?” And if it doesn’t, what else explains poor sleep or rising inflammation?

Next step. That’s the role of Vault Sleep OS: a system that helps you interpret your melatonin rhythms, place supplementation in context, and troubleshoot other drivers of sleep issues — when melatonin isn’t the lever.

References

• Rubio-Sastre P, Scheer FA, Gómez-Abellán P, Madrid JA, Garaulet M. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep. 2014 Oct 1;37(10):1715-9. doi: 10.5665/sleep.4088. PMID: 25197811; PMCID: PMC4173928.
• Candyce Hamel, Jennifer Horton, CADTH Health Technology Review, Melatonin for the Treatment of Insomnia: A 2022 Update 3
• Givler D, Givler A, Luther PM, Wenger DM, Ahmadzadeh S, Shekoohi S, Edinoff AN, Dorius BK, Jean Baptiste C, Cornett EM, Kaye AM, Kaye AD. Chronic Administration of Melatonin: Physiological and Clinical Considerations. Neurol Int. 2023 Mar 15;15(1):518-533. doi: 10.3390/neurolint15010031. PMID: 36976674; PMCID: PMC10053496.
• Tuft C, Matar E, Menczel Schrire Z, Grunstein RR, Yee BJ, Hoyos CM. Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults. Clin Interv Aging. 2023 Jan 12;18:49-59. doi: 10.2147/CIA.S361519. PMID: 36660543; PMCID: PMC9842516.
• Gobbi G, Comai S. Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep. Front Endocrinol (Lausanne). 2019 Mar 1;10:87. doi: 10.3389/fendo.2019.00087. PMID: 30881340; PMCID: PMC6407453.
• Baskett JJ, Broad JB, Wood PC, Duncan JR, Pledger MJ, English J, Arendt J. Does melatonin improve sleep in older people? A randomised crossover trial. Age Ageing. 2003 Mar;32(2):164-70. doi: 10.1093/ageing/32.2.164. PMID: 12615559.
• SMYTHE, G., LAZARUS, L. Growth Hormone Regulation by Melatonin and Serotonin. Nature 244, 230–231 (1973). https://doi.org/10.1038/244230a0
• Duffy JF, Wang W, Ronda JM, Czeisler CA. High dose melatonin increases sleep duration during nighttime and daytime sleep episodes in older adults. J Pineal Res. 2022 Aug;73(1):e12801. doi: 10.1111/jpi.12801. Epub 2022 May 13. PMID: 35436355; PMCID: PMC9288519.
• Luboshitzky R, Shen-Orr Z, Nave R, Lavi S, Lavie P. Melatonin administration alters semen quality in healthy men. J Androl. 2002 Jul-Aug;23(4):572-8. PMID: 12065466.
• Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, Baker G, Vohra S, Klassen T. Melatonin for Treatment of Sleep Disorders. Evidence Report/Technology Assessment No. 108. (Prepared by the University of Alberta Evidence-based Practice Center, under Contract No. 290-02-0023.) AHRQ Publication No. 05-E002-2. Rockville, MD: Agency for Healthcare Research and Quality. November 2004.
• Wang LM, Suthana NA, Chaudhury D, Weaver DR, Colwell CS. Melatonin inhibits hippocampal long-term potentiation. Eur J Neurosci. 2005 Nov;22(9):2231-7. doi: 10.1111/j.1460-9568.2005.04408.x. PMID: 16262661; PMCID: PMC2581482.
• Valcavi R, Zini M, Maestroni GJ, Conti A, Portioli I. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone. Clin Endocrinol (Oxf). 1993 Aug;39(2):193-9. doi: 10.1111/j.1365-2265.1993.tb01773.x. PMID: 8370132.
• Comai S, Gobbi G. Melatonin, Melatonin Receptors and Sleep: Moving Beyond Traditional Views. J Pineal Res. 2024 Oct;76(7):e13011. doi: 10.1111/jpi.13011. PMID: 39400423.
• Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013 May 17;8(5):e63773. doi: 10.1371/journal.pone.0063773. PMID: 23691095; PMCID: PMC3656905.
• Lelak K, Vohra V, Neuman MI, Toce MS, Sethuraman U. Pediatric Melatonin Ingestions – United States, 2012-2021. MMWR Morb Mortal Wkly Rep. 2022 Jun 3;71(22):725-729. doi: 10.15585/mmwr.mm7122a1. Erratum in: MMWR Morb Mortal Wkly Rep. 2022 Jul 08;71(27):885. doi: 10.15585/mmwr.mm7127a4. PMID: 35653284; PMCID: PMC9169525.
• Menczel Schrire Z, Phillips CL, Chapman JL, Duffy SL, Wong G, D’Rozario AL, Comas M, Raisin I, Saini B, Gordon CJ, McKinnon AC, Naismith SL, Marshall NS, Grunstein RR, Hoyos CM. Safety of higher doses of melatonin in adults: A systematic review and meta-analysis. J Pineal Res. 2022 Mar;72(2):e12782. doi: 10.1111/jpi.12782. Epub 2021 Dec 30. PMID: 34923676.
• Wyatt JK, Dijk DJ, Ritz-de Cecco A, Ronda JM, Czeisler CA. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep. 2006 May;29(5):609-18. doi: 10.1093/sleep/29.5.609. PMID: 16774150.
• Lauritzen ES, Kampmann U, Pedersen MGB, Christensen LL, Jessen N, Møller N, Støy J. Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes-A randomized placebo-controlled crossover trial. J Pineal Res. 2022 Aug;73(1):e12809. doi: 10.1111/jpi.12809. Epub 2022 Jun 9. PMID: 35619221; PMCID: PMC9540532.
• Marupuru S, Arku D, Campbell AM, Slack MK, Lee JK. Use of Melatonin and/on Ramelteon for the Treatment of Insomnia in Older Adults: A Systematic Review and Meta-Analysis. J Clin Med. 2022 Aug 31;11(17):5138. doi: 10.3390/jcm11175138. PMID: 36079069; PMCID: PMC9456584.
• Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61(3):253-278. doi:10.1111/jpi.12360. PMID: 27500468.
• Ferlazzo N, Andolina G, Cannata A, et al. Is Melatonin the Cornucopia of the 21st Century? Antioxidants (Basel). 2020;9(11):1088. doi:10.3390/antiox9111088. PMID: 33167396; PMCID: PMC7694322.
• Martín Giménez VM, de Las Heras N, Lahera V, Tresguerres JAF, Reiter RJ, Manucha W. Melatonin as an Anti-Aging Therapy for Age-Related Cardiovascular and Neurodegenerative Diseases. Front Aging Neurosci. 2022;14:888292. doi:10.3389/fnagi.2022.888292. PMID: 35721030; PMCID: PMC9204094.
• Wang LM, Suthana NA, Chaudhury D, Weaver DR, Colwell CS. Melatonin inhibits hippocampal long-term potentiation. Eur J Neurosci. 2005;22(9):2231-2237. doi:10.1111/j.1460-9568.2005.04408.x. PMID: 16262661; PMCID: PMC2581482.
• (Receptor distribution review used in text.) Melatonin receptor MT1/MT2 distribution in the mouse brain (review). PubMed PMID: 30937953. https://pubmed.ncbi.nlm.nih.gov/30937953
• Hardeland R. Melatonin and inflammation—Story of a double-edged blade. J Pineal Res. 2018;65(4):e12525. doi:10.1111/jpi.12525. PMID: 30242884 https://pubmed.ncbi.nlm.nih.gov/30242884
• Zhang HM, Zhang Y. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res. 2014;57(2):131-146. doi:10.1111/jpi.12162. PMID: 25060102. https://pubmed.ncbi.nlm.nih.gov/25060102
• Menczel Schrire Z, Phillips CL, Chapman JL, et al. Safety of higher doses of melatonin in adults: A systematic review and meta-analysis. J Pineal Res. 2022;72(2):e12782. doi:10.1111/jpi.12782. PMID: 34923676. https://pubmed.ncbi.nlm.nih.gov/34923676